275 related articles for article (PubMed ID: 31668516)
1. Patient decision aid for medication treatment for opioid use disorder (PtDA-MOUD): Rationale, methodology, and preliminary results.
Mooney LJ; Valdez J; Cousins SJ; Yoo C; Zhu Y; Hser YI
J Subst Abuse Treat; 2020 Jan; 108():115-122. PubMed ID: 31668516
[TBL] [Abstract][Full Text] [Related]
2. Development and usability testing of a patient decision aid for newly diagnosed relapsing multiple sclerosis patients.
Bansback N; Chiu JA; Carruthers R; Metcalfe R; Lapointe E; Schabas A; Lenzen M; Lynd LD; Traboulsee A
BMC Neurol; 2019 Jul; 19(1):173. PubMed ID: 31325961
[TBL] [Abstract][Full Text] [Related]
3. Developing a clinical decision support for opioid use disorders: a NIDA center for the clinical trials network working group report.
Bart GB; Saxon A; Fiellin DA; McNeely J; Muench JP; Shanahan CW; Huntley K; Gore-Langton RE
Addict Sci Clin Pract; 2020 Jan; 15(1):4. PubMed ID: 31948487
[TBL] [Abstract][Full Text] [Related]
4. The Lived Experiences of Pregnant and Parenting Women in Recovery Toward Medication Treatment for Opioid Use Disorder.
Titus-Glover D; Shaya FT; Welsh C; Roane L
Subst Use Addctn J; 2024 Jul; 45(3):367-377. PubMed ID: 38254261
[TBL] [Abstract][Full Text] [Related]
5. Medication for Opioid Use Disorder During Pregnancy - Maternal and Infant Network to Understand Outcomes Associated with Use of Medication for Opioid Use Disorder During Pregnancy (MAT-LINK), 2014-2021.
Miele K; Kim SY; Jones R; Rembert JH; Wachman EM; Shrestha H; Henninger ML; Kimes TM; Schneider PD; Sivaloganathan V; Sward KA; Deshmukh VG; Sanjuan PM; Maxwell JR; Seligman NS; Caveglia S; Louis JM; Wright T; Bennett CC; Green C; George N; Gosdin L; Tran EL; Meaney-Delman D; Gilboa SM
MMWR Surveill Summ; 2023 May; 72(3):1-14. PubMed ID: 37130060
[TBL] [Abstract][Full Text] [Related]
6. Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system.
Rawson RA; Rieckmann T; Cousins S; McCann M; Pearce R
Prev Med; 2019 Nov; 128():105785. PubMed ID: 31362002
[TBL] [Abstract][Full Text] [Related]
7. Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder.
Banta-Green CJ; Williams JR; Sears JM; Floyd AS; Tsui JI; Hoeft TJ
Drug Alcohol Depend; 2020 Feb; 207():107799. PubMed ID: 31865058
[TBL] [Abstract][Full Text] [Related]
8. Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.
Saunders EC; Moore SK; Walsh O; Metcalf SA; Budney AJ; Scherer E; Marsch LA
J Subst Abuse Treat; 2020 Apr; 111():54-66. PubMed ID: 32076361
[TBL] [Abstract][Full Text] [Related]
9. Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System.
Hawkins EJ; Malte CA; Gordon AJ; Williams EC; Hagedorn HJ; Drexler K; Blanchard BE; Burden JL; Knoeppel J; Danner AN; Lott A; Liberto JG; Saxon AJ
JAMA Netw Open; 2021 Dec; 4(12):e2137238. PubMed ID: 34870679
[TBL] [Abstract][Full Text] [Related]
10. Strategies to recruit rural primary care providers to implement a medication for opioid use disorder (MOUD) focused integrated care model.
Cloutier RM; Cole ES; McDonough BL; Lomauro DA; Miller JP; Talbert AL; Bear TM; Bridges NC; Foulds AL; Taber R; Gordon AJ; Cochran GT; Kmiec J; Donohue JM; Kelley D; DiDomenico E; Adair D; Pringle JL
Implement Res Pract; 2023; 4():26334895231152808. PubMed ID: 37091535
[TBL] [Abstract][Full Text] [Related]
11. Preliminary results of the evaluation of the California Hub and Spoke Program.
Darfler K; Sandoval J; Pearce Antonini V; Urada D
J Subst Abuse Treat; 2020 Jan; 108():26-32. PubMed ID: 31400985
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs.
Nota I; Drossaert CH; Taal E; Vonkeman HE; Haagsma CJ; van de Laar MA
Arthritis Res Ther; 2016 Oct; 18(1):252. PubMed ID: 27793171
[TBL] [Abstract][Full Text] [Related]
13. Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network Trial.
Hser YI; Ober AJ; Dopp AR; Lin C; Osterhage KP; Clingan SE; Mooney LJ; Curtis ME; Marsch LA; McLeman B; Hichborn E; Lester LS; Baldwin LM; Liu Y; Jacobs P; Saxon AJ
Addict Sci Clin Pract; 2021 Apr; 16(1):24. PubMed ID: 33879260
[TBL] [Abstract][Full Text] [Related]
14. Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs.
Winograd RP; Wood CA; Stringfellow EJ; Presnall N; Duello A; Horn P; Rudder T
J Subst Abuse Treat; 2020 Jan; 108():55-64. PubMed ID: 31277891
[TBL] [Abstract][Full Text] [Related]
15. Evaluating preferences for medication formulation and treatment model among people who use opioids non-medically: A web-based cross-sectional study.
Saunders EC; Budney AJ; Cavazos-Rehg P; Scherer E; Bell K; John D; Marsch LA
J Subst Use Addict Treat; 2024 Aug; 163():209383. PubMed ID: 38670531
[TBL] [Abstract][Full Text] [Related]
16. Opioid use-related stigma and health care decision-making.
Brown RL; Batty E; Lofwall M; Kiviniemi M; Kizewski A
Psychol Addict Behav; 2023 Mar; 37(2):222-227. PubMed ID: 35343742
[TBL] [Abstract][Full Text] [Related]
17. The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.
Reif S; Brolin MF; Stewart MT; Fuchs TJ; Speaker E; Mazel SB
J Subst Abuse Treat; 2020 Jan; 108():33-39. PubMed ID: 31358328
[TBL] [Abstract][Full Text] [Related]
18. Development of patients' decision aid for older women with stage I breast cancer considering radiotherapy after lumpectomy.
Wong J; D'Alimonte L; Angus J; Paszat L; Metcalfe K; Whelan T; Llewellyn-Thomas H; Warner E; Franssen E; Szumacher E
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):30-8. PubMed ID: 22331002
[TBL] [Abstract][Full Text] [Related]
19. Provider-directed marketing may increase prescribing of medications for opioid use disorder.
Nguyen T; Andraka-Christou B; Simon K; Bradford WD
J Subst Abuse Treat; 2019 Sep; 104():104-115. PubMed ID: 31370974
[TBL] [Abstract][Full Text] [Related]
20. Letting the sun shine on patient voices: Perspectives about medications for opioid use disorder in Florida.
Sharp A; Carlson M; Howell V; Moore K; Schuman-Olivier Z
J Subst Abuse Treat; 2021 Apr; 123():108247. PubMed ID: 33612190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
